Results 341 to 350 of about 14,382,480 (395)
Some of the next articles are maybe not open access.
Porcine factor VIII therapy in patients with factor VIII inhibitors
1995A review is presented of the use of porcine factor VIII (F.VIII) in patients with F.VIII inhibitors and acquired or congenital hemophilia. This review is drawn partly from the published literature and partly from an international survey of the use of porcine F.VIII in patients with congenital hemophilia conducted under the auspices of the ISTH F.VIII ...
Jay N. Lozier, C.R.M. Hay
openaire +3 more sources
JAMA: The Journal of the American Medical Association, 1985
To the Editor.— Dr Waddell and colleagues 1 described the use of porcine factor VIII concentrate in a patient with factor VIII inhibitor. They gave in detail the disadvantages and complications of this material and prothrombin complex concentrates.
openaire +3 more sources
To the Editor.— Dr Waddell and colleagues 1 described the use of porcine factor VIII concentrate in a patient with factor VIII inhibitor. They gave in detail the disadvantages and complications of this material and prothrombin complex concentrates.
openaire +3 more sources
FACTOR VIII STANDARDISATION [PDF]
The Lancet, 1981 T W, Barrowcliffe +4 more
openaire +3 more sources
Factor VIII and von Willebrand Factor
Thrombosis and Haemostasis, 1998IntroducationFactor VIII and von Willebrand factor are plasma glycoproteins whose deficiency or structural defects cause hemophilia A and von Willebrand disease, respectively (1). These diseases are the most common inherited bleeding disorders of man. Factor VIII and vWF are synthesized by different cell types and circulate in plasma as a tightly bound
André J. Vlot +3 more
openaire +4 more sources
[7] Factor VIII and factor VIIIa
1993Publisher Summary This chapter focuses on the role of factor VIII and factor VIIIa present in blood. The factor VIIIa apparently alters the active site structure of factor IXa to make it recognize the rate-limiting transition state for factor X activation, because its dominant kinetic effect is to increase the kcat.
Philip J. Fay +2 more
openaire +3 more sources
Characteristics of the Factor VIII Protein and Factor XIII in Various Factor VIII Concentrates
Scandinavian Journal of Haematology, 1980The in vitro properties of 5 factor VIII preparations (AHF‐Kabi, Hemofil Hyland, AHF‐Profilate Abbott, Kryobulin Immuno and Factorate High Purity Armour) and an ordinary cryoprecipitate were studied with reference to factor VIII clotting activity (VIII:C), factor VIII clotting antigen (VIILCAg), factor VIII related antigen (VIIIR:Ag) (EI, IRMA, CIE ...
Lars Holmberg +3 more
openaire +2 more sources
The Absorption of Human Factor VIII Neutralizing Antibody by Factor VIII
British Journal of Haematology, 1974Summary. A new technique has been devised for measuring the amount of human factor VIII neutralizing antibody that is absorbed by factor VIII. The method has been applied to factor VIII from normal donors and to factor VIII‐like antigen from haemophilic persons.
openaire +3 more sources
Porcine Factor VIII in Factor VIII Antibody-Positive Hemophiliacs
Journal of Interferon Research, 1994rected against the factor VIII protein, and completely or partially neutralizing the plasma coagulant activity of the clotting factor, is associated with a variety of diseases, and these antibodies are often the cause of the life-threatening bleeds. Such inhibitors, designated as acquired hemophilia, are uncommon (found in 0.2-1.0 previously normal ...
openaire +3 more sources